Evaluation of anti-nociceptive effect of venlafaxine in experimental animal model of mice
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20195263Keywords:
Venlafaxine, Tramadol, Tail immersion testAbstract
Background: Pain is an unpleasant sensation with varying subjective experience. Its management is always challenging for physicians particularly in case of chronic pain. Chronic pain and depression usually co-exist due to poor quality of life and increase in health care costs posing an individual to suffer from depression. Anti-depressants for pain management are being used successfully using since years. In this study venlafaxine, a newer anti-depressant drug was evaluated for anti-nociceptive activity, tail immersion test an analgesic animal model of albino mice.
Methods: Randomly selected albino mice of either sex with reaction time of <6 seconds were included in the study and divided into 7 groups with 6 mice in each group. Grouping was done based on the drug received i.e., venlafaxine 15, 30 and 60 mg/kg, tramadol 10 and 20 mg/kg, control group (normal saline) and combination group venlafaxine 15 mg/kg+tramadol 10 mg/kg. Drugs were administered by intra-peritoneal route.
Results: Venlafaxine (30 and 60 mg/kg), tramadol (20 mg/kg) and combination group venlafaxine (15 mg/kg+tramadol 10 mg/kg) has shown significant (p<0.001) increase in tail withdrawal latency compared to control group (normal saline) by tail immersion test. Venlafaxine potentiated anti-nociceptive activity of tramadol on concomitant administration with tramadol. Venlafaxine at 60 mg/kg has comparable anti-nociceptive effect to tramadol at 20 mg/kg.
Conclusions: Venlafaxine at doses of 30 and 60 mg/kg is having anti-nociceptive effect, but less potent than tramadol.
References
Mason P. Deconstructing endogenous pain modulations. J Neurophysiol. 2005;94(3):1659-63.
Kuhad A, Bishnoi M, Chopra K. Anti-nociceptive effect of duloxetine in mouse model of diabetic neuropathic pain. Indian J Exp Biol. 2009;47(3):193-7.
Wise TN, Fishbain DA, Holder-Perkins V. Painful physical symptoms in depression: a clinical challenge. Pain Med. 2007;8(2):S75-82.
Lepine JP, Briley M. The epidemiology of pain in depression. Hum Psychopharmacol. 2004;19(S1):3-7.
Rayner L, Hotopf M, Petkova H, Matcham F, Simpson A, Mc Cracken LM. Depression in patients with chronic pain attending a specialised pain treatment centre: prevalence and impact on health care costs. Pain. 2016;157(7):1472-9.
Barkin RL, Schwer WA, Barkin SJ. Recognition and management of depression in primary care: a focus on the elderly. A pharmacotherapeutic overview of the selection process among the traditional and new antidepressants. Am J Ther. 2000;7(3):205-26.
Barkin RL. Attributes, and advantages of venlafaxine overlooked. Formular. 1998;33:74-5.
Jha PK, Mazumdar B, Bhatt JD. Analgesic activity of Venlafaxine and its interactions with Analgesic activity of Venlafaxine and its interactions with Tramadol, celecoxib and amlodipine in mice tramadol, celecoxib and amlodipine in mice. Indian J Pharmacol. 2006;38(3):181-4.
Sikka P, Kaushik S, Kumar G, Kapoor S, Bindra VK, Saxena KK. Study of antinociceptive activity of SSRI (fluoxetine and escitalopram) and atypical antidepressants (venlafaxine and mirtazepine) and their interaction with morphine and naloxone in mice. J Pharm Bioall Sci. 2011;3:412-6.
Obara WI, Wordliczek J, Przewlocka B. Efficacy of Tramadol in combination with doxepin or Venlafaxine in inhibition of nociceptive process in the rat model of neuropathic pain: an isobolographic analysis. J Physiol Pharmacol. 2009;60(4):71-8.
Uyar M, Onal A, Uyar M, Dogru A, Soykan N. The antinociceptive effect of tramadol-venlafaxine combination on the paw withdrawal threshold in a rat model of neuropathic pain. Methods Find Exp Clin Pharmacol. 2003;25(5):361-5.
